UNITED THERAPEUTICS Corp (UTHR) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for UNITED THERAPEUTICS Corp (UTHR): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 65/100 — a percentile rank of UNITED THERAPEUTICS Corp’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $24.5B |
| P / E | 18.7× |
| P / S | 7.8× |
| EV / EBITDA | 15.2× |
| Gross margin | 86.1% |
| Operating margin | 44.4% |
| Net margin | 41.6% |
| Return on equity | 20.5% |
| ROIC | 25.4% |
| Revenue growth | 2.5% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is UNITED THERAPEUTICS Corp overvalued? P/E looks overvalued vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from UNITED THERAPEUTICS Corp’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact